Cervomed Inc (CRVO) Quarterly Institutional 13F Update (Q2 2026)

CRVO ranks #6956 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

37 institutions disclose a position in CRVO, but none treat it as a major bet — even Sabby Management, LLC, its most concentrated holder, allocates just 0.7% of its own portfolio to it.

Citizens Financial Group Inc/ri has trimmed its CRVO position for two straight quarters, cutting it by $36.4K while still holding $111.3K.

CRVO reported a net loss of $30.3M over the trailing twelve months.

• Not yet profitable — net loss of $30.3M over the trailing twelve months
• Revenue declined 95.7% year over year
• Net income declined year over year, from -$22.6M to -$30.3M
• Operating cash flow was negative, using $23.4M in cash
• Current ratio of 4.91x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.26x equity — within a conventional range